Go online to PeerView.com/BTV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple sclerosis (MS) is associated with complex pathophysiology and numerous management challenges, resulting in the need for a full and diverse range of treatment options. Bruton tyrosine kinase (BTK) inhibitors hinder actions of B cells and resident CNS innate immune cells (microglia) that can contribute to neuroinflammation and neurodegeneration and ultimately lead to disease progression and disability. Based on these mechanisms, BTK inhibitors have the potential to improve outcomes related to inflammation and neurodegeneration. In this PeerView educational activity based on a recent live web broadcast, our experts offer insights into the rationale for using BTK inhibitors to treat MS, current evidence regarding the use of BTK inhibitors in the treatment of MS, and the potential role of BTK inhibitors for individualized MS management based on available evidence and patient characteristics. Upon completion of this activity, participants should be better able to: Recognize the rationale for using Bruton tyrosine kinase (BTK) inhibitors to treat multiple sclerosis (MS), Summarize current evidence regarding the use of BTK inhibitors in the treatment of MS, Assess the potential role of BTK inhibitors for individualized MS management based on available evidence and patient characteristics.
View all episodes
